PMCB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PMCB is not a good buy right now for an impatient investor because there is no proprietary buy signal, no near-term catalyst flow (no news), weak fundamentals (zero revenue and continued losses), and the chart is sitting below the pivot with limited momentum. This is more of a watchlist/avoid until it reclaims key levels (especially the 0.915 pivot) with improving liquidity and sentiment.
Trend/momentum is mixed to slightly bearish near-term. Price (0.8316) is below the pivot (0.915) and just above first support S1 (0.814), meaning it’s trading in a lower zone where breakdown risk is elevated. RSI(6) at ~37 is weak/near-oversold but not a strong reversal signal by itself. MACD histogram is slightly positive (0.00195) but contracting, suggesting bullish momentum is fading rather than accelerating. Moving averages are converging, consistent with consolidation rather than a clean uptrend. Key levels: Support 0.814 then 0.752; Resistance 0.915 (pivot) then 1.015.
Intellectia Proprietary Trading Signals
Pattern-based probability suggests upside bias (70% chance of +1.84% next day; +8.84% next week; +11.49% next month), but without confirming momentum/volume signals this is not enough to justify an aggressive entry.
Technical: price is hovering close to support (0.814), so a bounce is possible if buyers defend that level.
Pattern analogs suggest a statistical upward drift over 1W–1M.
Options IV is extremely elevated, which can coincide with sharp price moves if a catalyst emerges.
No news in the past week—no visible event-driven catalyst to trigger an immediate rerating.
Price remains below pivot (0.
and MACD momentum is contracting, so upside follow-through is not confirmed.
Options market appears illiquid (0 volume today; small OI), which can amplify slippage and make sentiment signals unreliable.
Trading trends: hedge funds and insiders are neutral—no supportive accumulation signal.
Latest quarter: 2026/Q2. Revenue remains 0 (0% YoY), indicating no operating growth traction. Net income is still deeply negative at about -8.42M, though reported as improved YoY (+184.45%), and EPS is still negative (-1.24) though improved YoY (+217.95%). Overall: losses persist with no revenue base, so fundamentals do not support an “impatient buy now” setup.
No analyst rating trend or price target change data was provided, so Wall Street pros/cons cannot be validated from the dataset. From the available information (no revenue, ongoing losses, thin options/liquidity), the likely professional view would skew cautious/avoid until there is a concrete catalyst or operational progress.
